Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1 3Phase NA 1Phase 1/2 1

Status

Completed 3

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Tumor-Agnostic 1Head & Neck 1Gastrointestinal 1

Conditions

Neoplasms 2Pancreatic Neoplasms 1Head and Neck Neoplasms 1Adenocarcinoma 1

Interventions

Paclitaxel 292Gemcitabine 254Carboplatin 254Cisplatin 251Radiotherapy 219Cyclophosphamide 218Irinotecan 184pembrolizumab 181Docetaxel 174Bevacizumab 166Capecitabine 148Nivolumab 141Fluorouracil 132Dexamethasone 125Bortezomib 123Oxaliplatin 115Cytarabine 113Erlotinib Hydrochloride 112Temozolomide 110Sorafenib 110Doxorubicin 106Rituximab 105Leucovorin 105Etoposide 105Filgrastim 99Everolimus 97Lenalidomide 95Pemetrexed 90Ipilimumab 90fludarabine phosphate 84

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 1 × Completed × IPI-926 × Clear all
NCT01383538 2017-08-08

FOLFIRINOX Plus IPI-926 for Advanced Pancreatic Adenocarcinoma

University of California, San Francisco

Phase 1 Completed
15 enrolled
Gastrointestinal

Adenocarcinoma, Neoplasms, Pancreatic Neoplasms

NCT01255800 2014-01-31

Pilot Study of Cetuximab and the Hedgehog Inhibitor IPI-926 in Recurrent Head and Neck Cancer

University of Colorado, Denver

Phase 1 Completed
9 enrolled
Head & Neck

Head and Neck Neoplasms

NCT00761696 2012-06-21

A Phase 1 Study of IPI-926 in Patients With Advanced and/or Metastatic Solid Tumor Malignancies

Infinity Pharmaceuticals, Inc.

Phase 1 Completed
94 enrolled
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡